Abstract
We have investigated the beta-1 selectivity of a new beta-blocker, Bisoprolol, by comparing its effect on lipolysis induced by intravenous terbutaline infusion with that of Atenolol. At a dose of 5 mg, Bisoprolol had virtually no beta-2 blocking activity as measured by free fatty acid (FFA) release during terbutaline infusion. At a dose of 10 mg, Bisoprolol had a small but statistically insignificant effect on FFA release similar to 50 mg Atenolol. At a dose of 20 mg, Bisoprolol had significant beta-2 blocking activity. At lower doses, therefore, Bisoprolol is a very selective beta-blocker.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / pharmacology*
-
Adult
-
Atenolol / administration & dosage
-
Atenolol / pharmacology*
-
Bisoprolol
-
Dose-Response Relationship, Drug
-
Fatty Acids, Nonesterified / blood
-
Female
-
Humans
-
Infusions, Intravenous
-
Lipolysis / drug effects*
-
Male
-
Propanolamines / administration & dosage
-
Propanolamines / pharmacology*
-
Single-Blind Method
-
Terbutaline / pharmacology
Substances
-
Adrenergic beta-Antagonists
-
Fatty Acids, Nonesterified
-
Propanolamines
-
Atenolol
-
Terbutaline
-
Bisoprolol